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ABSTRACT
Objective: Markov models are increasingly used in economic evaluations
of treatments for osteoporosis. Most of the existing evaluations are
cohort-based Markov models missing comprehensive memory manage-
ment and versatility. In this article, we describe and validate an original
Markov microsimulation model to accurately assess the cost-effectiveness
of prevention and treatment of osteoporosis.
Methods: We developed a Markov microsimulation model with a lifetime
horizon and a direct health-care cost perspective. The patient history was
recorded and was used in calculations of transition probabilities, utilities,
and costs. To test the internal consistency of the model, we carried out an
example calculation for alendronate therapy. Then, external consistency
was investigated by comparing absolute lifetime risk of fracture estimates
with epidemiologic data.
Results: For women at age 70 years, with a twofold increase in the
fracture risk of the average population, the costs per quality-adjusted
life-year gained for alendronate therapy versus no treatment were esti-
mated at €9105 and €15,325, respectively, under full and realistic adher-
ence assumptions. All the sensitivity analyses in terms of model parameters
and modeling assumptions were coherent with expected conclusions and
absolute lifetime risk of fracture estimates were within the range of pre-
vious estimates, which conﬁrmed both internal and external consistency of
the model.
Conclusion: Microsimulation models present some major advantages
over cohort-based models, increasing the reliability of the results and being
largely compatible with the existing state of the art, evidence-based litera-
ture. The developed model appears to be a valid model for use in economic
evaluations in osteoporosis.
Keywords: cost-effectiveness, Markov model, microsimulation, modeling,
osteoporosis.
Introduction
Osteoporosis is an increasingly major health problem around the
world. It is a disease characterized by low bone mass with micro-
architectural disruption and increased skeletal fragility, leading
to increased fracture risk. Osteoporotic fractures results in sig-
niﬁcant morbidity, mortality [1], and reductions in quality of life
[2,3]. They also impose a huge ﬁnancial burden on health-care
systems. Moreover, with an aging population and increasing life
expectancy, their consequences are expected to increase in the
future.
In the cost-constrained environment of health care, economic
evaluation of various diagnostic and treatment strategies is
commonly used to help allocate resources in the most efﬁcient
manner [4–6]. Modeling is an important tool of economic evalu-
ation by its ability to: extrapolate results from one trial; combine
multiple sources of data; generalize results from one context to
another; deﬁne research strategy; and delineate areas of uncer-
tainty [7]. Nevertheless, models have limitations related to the
quality of the assumptions and the data utilized [8,9]. Thus,
models should be designed and conducted to reﬂect the complex-
ity of the real world [9].
During the past decade, signiﬁcant improvements were
achieved in the ﬁeld of pharmacoeconomic assessment of
osteoporotic interventions [6,10]. However, remaining limita-
tions relate to the effects of drugs on nonvertebral, nonhip frac-
tures, the assessment of adherence to treatment, and also the
failure to appropriately consider a lifetime horizon. Moreover,
most of the models are cohort-based [11], thereby limited in their
ability to deal simultaneously and accurately with the complex
interactions of patient, intervention, and clinical events. Speciﬁ-
cally, this approach is limited by the “memoryless” feature of the
process, which is known as the Markov assumption [12]. This
assumption means that once a patient has moved from one state
to another, the model will have “no memory” regarding where
the patient came from. When transition probabilities depend
on prior events (such as in osteoporosis), this dependence or
“memory” should be reﬂected in the model [13]. In many cohort
models, “post-fracture states” have therefore been used for per-
sistent changes in transition probabilities and utilities after hip
and vertebral fractures. Nevertheless, future events are poten-
tially inaccurately estimated by this approach [14].
Examples of the weaknesses of this approach follow. First,
because of the desire to avoid an unmanageable number of health
states, cohort models have restricted the number of disease states
and transitions between them. For example, it has been fre-
quently assumed that patients who have had a hip fracture
cannot experience any future nonhip fracture [11]. This does not
reﬂect realistic clinical perspectives because patients can deﬁ-
nitely have other fractures after a nonfatal hip fracture. Addi-
tionally, patients in “postfracture state” might have a previous
history of one, two, or more prior fractures but may be assigned
the same transition probabilities, costs, and utility. This is also
inconsistent with epidemiologic studies. Various studies have
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shown a relationship between utility values and the number and
location of prior fractures [15–18]; thus, if a model fails to record
all the prior fractures, the utility value of patients with multiple
prevalent fractures will be overestimated. Moreover, prior frac-
tures were also shown to dramatically increase the risk of sub-
sequent fractures [19,20] and there should be a record of all
fractures to accurately assess this increased risk. Third, the resi-
dential status of a patient, deﬁned as community- or nursing
home dwelling, may affect long-term costs. The failure to track
residential status will, for example, inappropriately add costs to
a patient with an incident fracture who already lives in a nursing
home [14].
Microsimulation models address the above weaknesses and
have the potential to be more accurate than cohort models. Their
use has increased dramatically with the speed of computing
technology and they now begin to supplant cohort models in
health-care technology assessment [21]. In the setting of
osteoporosis, a Monte Carlo microsimulation identiﬁes indi-
vidual subjects to track their characteristics and individual
disease histories [22]. Factors such as prior fracture and current
residential status are used to calculate transition probabilities,
utility values, and costs. Therefore, microsimulation models
require no restrictive assumptions regarding patient movement to
health states and allow assessing the impact of prior fractures
without creating a large, incomprehensible and unmanageable
number of health states. The infrequent use of microsimulation
in osteoporosis is due to the greater variance in results because of
random variation in individual outcomes, and of the much
greater detail required for data sets (to be modeled) than would
be required for cohort-based models. These factors have been
proposed as the rationale for supporting the use of cohort-based
approaches [23]. Potential drawbacks with microsimulation
models include the computation burden when the joint uncer-
tainty in all parameters is assessed using probabilistic sensitivity
analysis [12].
We believe that there is value in developing microsimulation
models in the ﬁeld of osteoporosis [23]. The objective of this
study was therefore to develop and validate a new Markov
microsimulation model for the assessment of the cost-
effectiveness of the prevention and treatment in osteoporosis. In
this article, we present the model and we validate it through an
empirical illustration.
Methods
The developed model was constructed using decision analysis
software (TreeAgePro 2006 Suite, release 0.4, TreeAge Software,
Inc., Williamstown, MA).
Model Structure
Because osteoporosis is a chronic disease characterized by a
recurrence of events and when the fracture risk is continuous
over time, a Markov modeling technique is appropriate [24]. The
structure of the model is shown in Figures 1 and 2. It has been
suggested that the model should be kept as simple as possible to
be understandable, while capturing the underlying essentials of
the process and interventions [13]. Therefore, the model consists
of six states: “no fracture,” “death,” “hip fracture,” “vertebral
fracture,” “forearm fracture,” and “other fracture.” This last
state represents all other osteoporotic fractures [25] (e.g.,
humerus, pelvis, or distal femur).
The cycle length of the model is 1 year because events rarely
occur more than once a year and most of the data sources, such
as fracture disutility and fracture cost, are calculated on this
frequency. The model follows the patients until they are dead or
they reach the age of 105 years.
All the transitions between health states other than death are
possible. So, in every cycle and regardless of the current state,
each individual has a probability of having a fracture based on
fracture risk, of having no fracture, or of dying based on mor-
tality rates. If an individual is in a fracture state, she might have
a new fracture (all fracture types are possible), or move to the
“no fracture” state, or die. If an individual were to die, she would
remain in the “death” state for the rest of the simulation.
A branch was created to keep track of residential status
(either in the community or in a nursing home) for an individual
with a hip fracture because this fracture type is associated with
admission to a nursing home. Once a patient enters a nursing
home, we assume that he/she will stay there for the rest of his/her
life. We also assume a discount rate of 3% for costs and of 1.5%
for health beneﬁts for the base-case analysis, as recommended for
health economic evaluations in Belgium, the country of reference
for the present article [26].
Death
0
No fracture
1
Death
P_DeathHip
Death
Nursing home
P_NH
Community
1-P_NH
Survival
1-P_DeathHip
Hip fracture
0
Vertebral fracture
0
Forearm fracture
0
Other fracture
0
Strategy
Figure 1 Markov model structure for each strategy. P_DeathHip and P_NH
are, respectively, probabilities of death in the year after hip fracture and
probabilities of being admitted to a nursing home after hip fracture for surviving
patients.
Death
P_Death
No fracture
P_NoFx
Hip fracture
P_Hip
Vertebral fracture
P_Vert
Forearm fracture
P_Forearm
Other fracture
P_Other
Figure 2 Expanded subtree for all health state other than death. P_Death,
P_NoFx, P_Hip, P_Vert, P_Forearm, P_Other are transition probabilities of
death, no fracture, hip fracture, vertebral fracture, forearm fracture, and other
fractures, respectively. Figure 2 needs to be applied to all health states other
than death in Figure 1 (represented by a green circle).
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Memory Integration
In a practical sense, tracking patient history can be done with
so-called tracker variables [22]. In our model, such variables
were created to record the number of each fracture type and the
residential status for all patients. They were then used in calcu-
lations of transition probabilities, utilities, and costs to reﬂect the
patient history.
To illustrate how the model integrates memory, an example is
shown in Figure 3. Our hypothetical patient began the process in
the state “no fracture” and had corresponding transition prob-
abilities, utility, and cost. It was assumed that the patient had
suffered a hip fracture at stage 1, and so he moved to the state
“hip fracture” associated with a lower utility, a higher cost, and
different transition probabilities. The tracker variable that counts
the number of hip fractures was then increased by one unit and
was then used in all ensuing cycles to adjust transition probabili-
ties, utilities, and costs to reﬂect the long-term impact of hip
fracture on these components. Using this technique, “post-
fracture states” and restrictive assumptions regarding patient
transitions to health states used in cohort models are not needed.
Fracture Probabilities
Transition probabilities depend on the individual’s characteris-
tics (age, gender, bone mineral density, number of clinical risk
factors), presence or absence of prior fractures, presence or
absence of therapy and probabilities should also depend on the
residential status of the individual. Patients are entered in the
model one at a time with the same or different characteristics.
Their transition probabilities may differ according to fracture
events during the process. The effect of treatment is modeled as
a relative risk reduction in population-speciﬁc fracture risk [27].
Treatment length in the model should be based on the duration of
clinical trials, often limited to 3 or 5 years for anti-osteoporotic
therapy.
Initial probabilities should be taken from epidemiologic data
speciﬁc to the country and need to be adjusted to accurately
reﬂect the fracture risk in the target population in comparison
with that of the general population. The incidence of a ﬁrst
fracture in Belgium was estimated in a previous study [28].
Our model incorporates an increased risk of subsequent frac-
ture for individuals who have a prior fracture of the same loca-
tion. These increased relative risks are 4.4, 2.3, 3.3, and 1.9 for
vertebral, hip, forearm, and “all-other osteoporotic” fractures,
respectively [20]. An increased risk of subsequent fractures at
sites different from that of prior fractures is not modeled because
fracture incidence (at a speciﬁc site) was estimated regardless of
the presence of fractures at other sites, and a multiplicative
hypothesis could not be supported at this time with one excep-
tion. An increased relative risk of 2.3 is modeled for a hip
fracture after a vertebral fracture based on existing literature
[20,29–31]. All these increased relative risks were increased by a
factor of 1.7 during the year after the fracture (calculated based
on the study of Johnell et al. [2004]) [30], except in the case of
vertebral fracture, and were reduced by 10% per each decade
above the age of 70 years [19]. Further fractures of the same type
are assumed to have no additional effect because of the absence
of data providing an accurate relationship between the number
of prior fractures and an increased risk.
Mortality Rates
Transition probabilities to death depend on individual character-
istics (age and gender) and the presence or absence of prior
fractures. Mortality rates according to age and gender are avail-
able from ofﬁcial estimates speciﬁc to the country [32]. Projected
mortality rates were also tested in sensitivity analysis. Such
estimates take account of progressive mortality reductions in
advanced age and have been carried out in Belgium [33].
The impact of prior fracture on mortality is controversial
[34]. Most studies have noted a substantial increase in mortality
in the ﬁrst year after a hip or a clinical vertebral fracture [1,35–
37]. The duration of excess mortality remains unclear and the
studies differ regarding the existence of a long-term effect of
fractures [38]. Some studies have shown persistent and long-term
increased mortality [35,38–40]. Others have suggested that the
increased mortality after a hip fracture is limited to the ﬁrst year
after fracture and that no or only modest increased mortality was
evident during subsequent years of follow-up [34,41,42].
To avoid an overestimation of the beneﬁcial effect of treat-
ment on mortality, it is important to take only into account most
of the excess mortality [27] attributable to fractures, which could
be reduced through fracture prevention. Therefore, we conserva-
tively assumed that only 25% of the excess mortality after a hip
or vertebral fracture can be directly or indirectly attributable to
the fractures themselves [1,41,43,44].
In our base-case analysis, we assumed a ﬁrst year and a
subsequent year excess mortality after hip and clinical vertebral
fracture. Excess mortality after a hip fracture was obtained from
the study of Oden et al. (1998) [45]. This study gave detailed and
Figure 3 Example of memory integration. QALY, quality-adjusted life-year.
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conservative estimates in comparison with other studies [1,46].
The increased mortality after a clinical vertebral fracture has
been found to be very similar and even slightly higher than those
of a hip fracture [1,35,41,43]. Therefore, we suggested in a
conservative approach an impact of clinical vertebral fracture
similar to that of hip fracture.
It is also assumed that other osteoporotic fractures, including
forearm fractures, are not associated with an increased mortality
that could be attributable to the fracture, and this is consistent
with published studies [35,37]. We also suggested in a conserva-
tive manner that a second and further fractures at the same site
will cause no greater excess mortality. Nevertheless, we do
assume an interaction of excess mortality between a vertebral
and an hip fracture, based on the result of Cauley et al. (2000)
[35].
Health State Utility Values
The utility values associated with each health state depend on
age, presence or absence of prior fractures, and may also depend
on the presence or absence of therapy. A recent study [47] sys-
tematically reviewed the utility estimates for health states asso-
ciated with osteoporosis and suggested reference values for
countries that would like to carry out cost-utility analyses but are
not able to process country-speciﬁc study (which requires both
time and money). We used these references values for the general
population level as well as relative reductions due to fractures
(Table 1).
Our microsimulation model gives the possibility of having
several fractures at the same or at different sites. Such an
improvement requires an estimation of or an assumption about
the consequences of fracture interactions on utility value.
Previous models have assumed that when a patient suffers a
fracture for a second or further time, only the reduction in
quality of life resulting from one fracture is taken in consider-
ation [48]. Nevertheless, it seems likely that a person who suf-
fered two fractures has a lower level of quality of life (all other
things being equal) than an individual who has suffered only
one of these two fractures. This assumption was conﬁrmed by
recent studies showing that the number of fractures is a signiﬁ-
cant determinant of quality of life [3,15–18,49]. We, therefore,
assumed that when a second fracture occurs at the same site as
a previous one (e.g., hip or clinical vertebral), the subsequent
disability and reduction in quality of life can be attributed par-
tially to the ﬁrst fracture and partially to the new fracture
event. Therefore, to avoid overestimation of disability, due to
both fracture events, in case of the occurrence of a second
fracture at the same site, we reduced by 50% the disability
allocated to the ﬁrst fracture event. This assumption seems
coherent and even conservative for vertebral fractures because
some studies have shown that quality of life reduces with the
number of previous vertebral fractures and that it has almost
an additive effect [18]. For an individual with both a hip and
vertebral clinical fracture, the total impact on utility value
equals the sum of the impacts related to each of the fractures.
This result is coherent with the study of Tosteson et al. (2001)
[15], which suggests that the impact of the two fractures is even
greater than the sum of the impacts related to each of the frac-
tures. When an individual with a prior hip or clinical vertebral
fracture has a forearm or other fracture, the long-term impact
of the previous fracture is reduced by half. Nevertheless, there
will be no more interaction after the year of this latest fracture
because forearm and other fractures have no effect on utility
value in subsequent years.
Table 1 Model parameters
Parameter Values Distribution Source
Fracture risk Depending on age and fracture type Uniform (0.85*BV to 1.15*BV) [28]
Probability of admissions to a nursing home Depending on age Uniform (0.75*BV to 1.25*BV) [51]
Relative risk of a prior fracture on future
fracture risk (for age range 50 to 60)
Prior hip implies future hip (RR) 2.30 Uniform (1.20 to 3.40) [20]
Prior CV implies future CV (RR) 4.40 Uniform (3.50 to 5.30) [20]
Prior forearm implies future forearm (RR) 3.30 Uniform (1.65 to 4.95) [20]
Prior other implies future other (RR) 1.90 Uniform (1.65 to 2.15) [20]
Prior CV implies future hip (RR) 2.30 Uniform (1.90 to 2.70) [20]
Mortality rates
Excess mortality attributable to fracture 0.25 Uniform (0.20 to 0.30) [41,43]
Utility values
Hip fracture, ﬁrst year* (RR) 0.797 Beta (a = 655, b = 167) [47]
Hip fracture, subsequent years* (RR) 0.899 Beta (a = 2,007, b = 225) [47]
CV fracture, ﬁrst year* (RR) 0.720 Beta (a = 169, b = 66) [47]
CV fracture, subsequent years* (RR) 0.931 Beta (a = 1,021, b = 76) [47]
Forearm fracture, ﬁrst year* (RR) 0.940 Beta (a = 326, b = 21) [47]
Other fracture, ﬁrst year* (RR) 0.91 Beta (a = 318, b = 31) [47]
Direct fracture costs (in €)
Hip fracture, ﬁrst year From 16,457 to 20,998 Uniform (0.85*BV to 1.15*BV) [51,52]
CV fracture, ﬁrst year 2,429 Uniform (0.85*BV to 1.15*BV) [56,57]
Forearm fracture, ﬁrst year 2,159 Uniform (0.85*BV to 1.15*BV) [55]
Other fracture, ﬁrst year 3,573 Uniform (0.85*BV to 1.15*BV) [56,57]
Long term care > 1 year after hip fracture
(for those who enter nursing homes)
19,821 (<70 years)–15,247
(>70 years)
Uniform (0.85*BV to 1.15*BV) [54]
Intervention
Hip fracture efﬁcacy (RR) 0.62 Log-normal (95% CI 0.40–0.98) [58]
CV fracture efﬁcacy (RR) 0.56 Log-normal (95% CI 0.46–0.68) [58]
Forearm fracture efﬁcacy (RR) 0.67 Log-normal (95% CI 0.34–1.31) [58]
Other fracture efﬁcacy (RR) 0.81 Log-normal (95% CI 0.68–0.97) [58]
Compliance 0.705 Uniform (0.80*BV to 1.20*BV) [67]
*Relative reduction in utility value represents the proportional loss of quality-adjusted life-year due to the fracture.
BV, base value; RR, relative risk; CI, conﬁdence interval; CV, clinical vertebral.
690 Hiligsmann et al.
Costs
Belgian methodological guidelines for pharmacoeconomic evalu-
ations recommend a direct health-care cost perspective [26].
These encompass intervention costs related to diagnosis and
intervention (e.g., drugs, surgical procedure), together with
adverse events attributable to the intervention as well as direct
health-care costs related to the disease. Indirect costs (e.g., pro-
ductivity losses) as well as unrelated health-care costs in life-years
gained should not be included in the reference case analysis [26]
and were therefore not included in our model.
The cost of a fracture is divided into cost during the ﬁrst year
after the fracture and long-term costs, which may persist for
several years and even for the rest of the patient’s lifetime. Cost
estimates are expressed in €2006 and were inﬂated by consumer
price indexes when necessary [50]. Direct hip fracture costs
include hospitalization cost and additional costs during the year
after the fracture. In Belgium, this has ranged from €16,457 to
€20,998 according to age based on the hospitalization [51] and
extra costs during the year after the fracture [52], both estimated
in 1996.
Hip fractures are also associated with long-term costs.
These long-term costs have been based on the proportion of
patients being institutionalized after the fracture. This propor-
tion was shown to range from 5% (for the age range 50–60
years) to 30% (for women aged 90 years or more) in Belgium
[51]. In economic models, it is assumed that women who enter
into a nursing home will remain there for the rest of their lives
[11] and thus, the annual cost of being in the nursing home is
added into the model for each remaining year of the woman’s
life. Nevertheless, this is a simpliﬁcation providing a cost over-
estimation because the individuals might have been institution-
alized later in life in any case, regardless of their hip fracture.
Therefore, it is important to estimate only the long-term costs
attributable to hip fracture, which could be reduced through
fracture prevention [53].
To estimate the total cost attributable to fracture, we ﬁrst
reduced the proportion of individuals in a nursing home after
a fracture (= 100%) each year by the institutionalization rate
in the general population. The annual hip fracture cost was
obtained by multiplying the proportion of fractures related to
institutionalization with the annual cost of institutionalization
(= €83.5 per day [54], so €30,495 per year). Then, we summed
these values for each year until the age of average life expect-
ancy. The proportion of long-term costs attributable to hip
fracture was estimated respectively at 65% and 50% for
women less than and more than the age of 70 years. So, a
50-year-old woman institutionalized after a hip fracture would
have an annual long-term cost equal to 0.65 ¥ €30,493 =
€19,820.
Forearm fracture costs were estimated at €2159 [55]. Other
fractures have been quantiﬁed relative to hip fracture on the basis
of their costs [56,57]. We assumed that the costs of other
osteoporotic fractures represent 25% of hip fracture costs, in line
with the study of Gabriel et al. (2002) conducted between 1989
and 1992 [56]. This study does not integrate the cost of the
nursing home in comparison with the study of Autier et al.
(2000). We, therefore, reduced hip fracture costs by 50% of their
extra costs before applying the proportion factor. The costs of
other fractures were then estimated at €3573. Clinical vertebral
fracture costs were estimated at €2429 based on a proportion
factor of 17% relative to hip fracture [56,57]. The long-term
costs of fractures other than hip have been rarely studied. There-
fore, we conservatively assumed that there are no associated
long-tem costs.
Empirical Illustration
To illustrate the model and the impact of model assumptions, an
example calculation was carried out. In the base-case analysis,
we assumed that women aged 70 years old with a twofold
increase in fracture risk received a 5-year alendronate therapy,
the most widely prescribed osteoporosis treatment worldwide.
The increased risk corresponds approximately to the fracture risk
of women with two clinical risk factors or women with one
previous fracture (who have on average a fracture risk increase of
1.86 [19]). The clinical effectiveness of alendronate in the treat-
ment of women with osteoporosis has been extensively docu-
mented [58]. A recent review suggested relative risks of 0.62 for
hip fracture, 0.56 for clinical vertebral fracture, 0.67 for forearm
fracture, and 0.81 for other fractures [58]. These relative risks
have been used in recent studies assessing the cost-effectiveness of
alendronate therapy [48,59,60] and were therefore selected for
this analysis. After a 5-year treatment period, we assumed that
the treatment effect persisted for 5 years (i.e., “offset-time”), in
line with clinical studies [61–64] and assumptions used in previ-
ous models [27,59,65]. The risk reduction was assumed to
decline linearly to zero during this period.
Adherence to antiosteoporosis medications is currently low
and is associated with decreased antifracture efﬁcacy [66]. In a
recent study assessing adherence to bisphosphonates including
alendronate [67], only 70%, 58%, 40%, 25%, and 20% of
patients were respectively found to be persistent after 3 months,
6 months, 1 year, 2 years, and 5 years of therapy. Therefore, we
assumed that 30%, 12%, 18%, and 15% of patients stopped
drug therapy after 3 months, 6 months, 1 year, and 2 years. No
treatment effect was assumed for patients who discontinued
treatment after 3 months, and offset time for nonpersistent
patients was assumed to be the same as their treatment period.
Compliance, deﬁned as how appropriately the treatment was
correctly taken, was estimated at 70.5% for persistent women in
the same study [67]. Medication costs and fracture reduction
efﬁcacy were assumed to be proportional to compliance.
The annual cost of the original alendronate therapy was
estimated at €421.18 (Fosamax, 70-mg tablet packages, once per
week; Merck & Co., Whitehouse Station, NJ). In accordance
with previous standard assumptions regarding the monitoring of
osteoporotic treatments [11], we assumed that treatment was
associated with one annual physician’s visit (€20) and an addi-
tional bone densitometry measurement every second year (esti-
mated at €47). No adverse events were assumed in the base-case
analysis.
Probabilistic Sensitivity Analyses
Probabilistic sensitivity analyses were performed using a beta
distribution for quality-adjusted life-year (QALY) disutility and a
log-normal distribution for the relative fracture risk of treatment
(Table 1), as recommended by Briggs’s book [12]. Uniform dis-
tributions were also used for fractures risks, for probability of
admissions to a nursing home, for excess mortality after a frac-
ture, for fracture costs, and for the impact of a prior fracture on
future fracture risk. Analyses were performed with 150 simula-
tions (each parameter was randomly selected from the distribu-
tion) and with 25,000 trials per analysis. An acceptability curve
was then constructed from the incremental cost and QALYs
between different strategies for the 150 simulations.
Model Consistency
Assessing the consistency of the model was classiﬁed into
three categories: internal consistency, external consistency,
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and between-model consistency. To investigate the internal
consistency, different sensitivity analyses in terms of model
parameters and modeling assumptions were carried out. External
consistency was investigated by comparing absolute lifetime risk
of fracture estimates with estimates based on epidemiologic data
and other studies. And between-model consistency was assessed
by comparing some features of our model with those of existing
models and by comparing results provided by our model with
that of Zethraeus, available online [11], for the same example
calculation.
Results
Internal Consistency
Table 2 gives the cost per QALY gained (in €) for alendronate
therapy versus no treatment. For each case, a large number of
microsimulations (200,000) were carried out to guarantee the
stability of the results. The cost per QALY gained in the base case
was €9105 and €15,325, respectively, under full and realistic
adherence assumptions. The univariate sensitivity analyses based
on model assumptions suggested that the cost per QALY gained
was higher when we did not integrate QALY disutility for prior
fractures and when there was no increased risk due to prior
fractures. The impact of the number of prior fractures on utility
value was however limited. When taking account of the full
nursing home costs and not only of the proportion attributable to
fracture, the efﬁciency was greatly overestimated.
Cost per QALY gained was lower when we used the projected
mortality rates. It is also interesting to note that using projected
mortality rates compensates for the incremental cost-
effectiveness ratio increase due to the deletion of excess mortality
after the ﬁrst year. Therefore, our base-case assumption
(medium-term excess mortality and actual mortality rates) gives
similar results to an assumption using projected mortality rates
and only ﬁrst-year excess mortality.
The cost per QALY gained was shown to decrease with
increasing age, fracture risk, fracture disutility, treatment efﬁcacy,
offset time, and with decreasing intervention cost and discount
rates. The cost per QALY gained was also shown to be lower
where quality of life increases during therapy and higher when
adverse events are assumed.
The cost-effectiveness acceptability curves showed the prob-
ability that an intervention is cost-effective as a function of the
decision-maker’s willingness to pay. At an assumed willingness to
pay of €45,000 and for women aged 70 years, there were a
96.7% and a 91.3% chance, respectively, that treatment would
be cost-effective under full and realistic adherence assumptions
(Fig. 4). These values were 96.0% and 79.3% for women aged
65 years.
External Consistency
Absolute lifetime risk of hip fracture and of any osteoporotic
fracture was estimated respectively at 16.5% and 45.3% for
women aged 60 years. The average age at ﬁrst hip and at
Table 2 Cost per QALY gained (in €) of alendronate therapy versus no
treatment: base-case and sensitivity analyses based on model assumptions
and model parameters
Assumptions or parameters
varied in the sensitivity analysis
Full
adherence
Realistic
adherence
Base case 9,105 15,325
Model assumptions
Full QALY disutility of prior fractures when a
new fracture occurs
8,641 14,777
No QALY disutility of prior fractures when a
new fracture occurs
10,310 16,830
No increased risk due to prior fractures 17,979 23,634
50% of increased risk due to prior fractures 13,154 20,317
Projected mortality rates 6,440 13,238
Excess mortality in only the ﬁrst year after
fracture
11,266 16,186
Projected mortality rates and excess mortality
in only the ﬁrst year after fracture
7,510 14,503
Half of the excess mortality of prior fractures
when a new fracture occurs
8,121 13,749
Full nursing home cost 736 7,650
Other fractures excluded 10,102 17,017
Time horizon: 95 years 10,095 15,831
Model parameters
Discount rates: 5% 18,945 30,445
Treatment initiation at 65 years 20,371 26,920
Treatment initiation at 75 years CS 1,718
0.75 time base-case fracture disutility 13,289 22,930
0.75 time base-case fracture costs 13,314 21,659
0.50 time base-case fracture risks 47,340 60,673
0.75 time base-case fracture risks 20,924 31,826
Excess mortality attributable to fractures: 0.50 8,217 12,216
0.50 time base-case admissions to nursing
home after hip fracture
13,449 16,562
Treatment cost 20% higher 15,770 24,243
Treatment efﬁcacy 20% lower 20,526 24,799
Offset-time 40% lower 14,994 25,245
QALY increase by 1% during therapy 4,984 9,884
Adverse events: 10€ per year of treatment 9,922 16,554
CS, cost saving; QALY, quality-adjusted life-year.
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Figure 4 Cost-effectiveness acceptability curves.
Full Ad., full adherence; QALY, quality-adjusted life-
year; Real Ad., realistic adherence.
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ﬁrst osteoporotic fracture was 82.37 years and 74.61 years,
respectively.
Between-Model Consistency (Table 3)
The most often used models in the ﬁeld of osteoporosis are the
model of Zethraeus et al. [11], the model of Tosteson et al. [27]
and the National Institute for Clinical Excellence (NICE) model
[68]. The ﬁrst two models are cohort-based, while the third is a
microsimulation model. The ﬁrst model was limited by restrictive
assumptions about transitions between states. For example,
patients with a prior hip fracture cannot experience any future
nonhip fracture. This model, populated with Swedish data, has
the advantage to be based on a great local database and was
based on a societal perspective. The model of Tosteson deﬁnes
more health states and allows patients with prior hip fracture to
have future nonhip fracture. These two models do not integrate
an increased risk after a prior fracture, in comparison with the
NICE model. The time horizon of the NICE model is constrained
to a 10-year period. Nevertheless, different studies have shown
that a prior fracture has a long-term effect on future fracture risk
and quality of life and that hip fracture is associated with long-
term costs. Therefore, the required time horizon to evaluate fully
the beneﬁt of a particular intervention may be very long [69] and
the use of a lifetime horizon is then recommended for a chronic
disease such as osteoporosis [26,70]. A recent microsimulation
model of Schousboe et al. [65] used a lifetime horizon and incor-
porates an increased relative risk for a subsequent fracture after
a prior fracture of the same location.
In the model of Zethraeus [11] populated with Swedish data,
alendronate therapy was cost saving compared with an incremen-
tal cost per QALY gained of €9105 in our model under full
adherence assumption. The differences can be explained by several
factors. A key one relates to the signiﬁcantly greater fracture
incidence, estimated to be 30% to 40% for ﬁrst fractures, in
Sweden compared to Belgium [28,71]. This single factor would
alter the incremental cost-utility by respectively €5526 and €9032.
Discussion
Economic evaluation has become increasingly important in
the ﬁeld of osteoporosis because of the growing awareness of
osteoporosis, the development and introduction of new treat-
ments, and the extending role of economic evaluations in health-
care decision-making process. Reliability and the subsequent
interest in these evaluations depend both upon the methodologi-
cal aspects of the model itself and on the quality of the data
feeding the model. During the last decade, a lot of signiﬁcant
improvements have been achieved in the quality of economic
evaluations in the ﬁeld of osteoporosis. Nevertheless, most of the
existing models are cohort-based models lacking comprehensive
memory management and versatility. The major weakness of this
approach is that it does not integrate memory and thus future
events do not depend on prior events. Such simpliﬁcations could
lead to potentially inaccurate estimations. Some examples were
reviewed in the introduction.
Improving the quality of modeling is becoming a priority
issue. Microsimulation models are beginning to supplant cohort-
based models in health-care decision-making [21]. These models
undoubtedly have a better ability to represent the complexity and
the heterogeneity of pathology such as osteoporosis. The major
advantage of these models is that the full patient history may be
recorded and thus, in the case of osteoporotic models, factors
such as prior fracture and residential status can be used in cal-
culations of transition probabilities, costs, and utilities. There-
fore, no restrictive assumptions regarding patient transitions to
health states are needed and this method allows assessing the
impact of prior fractures without creating a large and unman-
ageable number of health states. Moreover, these models help in
dealing with future data regarding the consequences of fracture
interactions. In spite of their advantages, microsimulation
models have rarely been used in the ﬁeld of osteoporosis because
they also present limitations. First, microsimulation models
require more detailed and sophisticated data. An improvement
over time is, however, evident in the collection of data. Then,
these models are associated with a greater variance in results.
Finally, the computation burden is another potential drawback.
In this article, we present a new Markov microsimulation
model to accurately assess the efﬁcacy of osteoporosis manage-
ment. This model has been constructed in accordance with good
modeling practice [13,70,72,73], was based on the latest devel-
opments and modeling challenges addressed in previous models
and reviews and improvements in data collection related to
osteoporosis, and has been validated. First, internal consistency
was conﬁrmed by univariate sensitivity analyses in terms of
model parameters and modeling assumptions and by probabilis-
tic sensitivity analyses. All of these were consistent with expected
conclusions. Second, our absolute lifetime risks of fracture esti-
mates are within the range of previous estimates [27,45,71,74–
78]. External consistency was also conﬁrmed by an additional
analysis that has recently estimated the effect of changes in base-
line population risk and changes in life expectancy on absolute
lifetime fracture risks [28]. Third, our model has many important
features of models in osteoporosis such as a lifetime horizon, an
increased risk after a prior fracture, and no restrictive assump-
tions about transitions between states. Moreover, the results
provided by our model seem coherent and do not signiﬁcantly
diverge from the model of Zethraeus, which conﬁrmed between-
model consistencies. More speciﬁc comparison with existing
models is however needed and should include the comparison of
the same treatment in the same population.
In addition to the advantages gained by choosing the micro-
simulation modeling, we only modeled long-term fracture costs
attributable to the hip fracture event and our model is the ﬁrst to
incorporate a relation between utility values and the number
of prior fractures. Although the effect on cost-effectiveness is
limited, this assumption was supported by the literature. Further-
more, our model discriminates between ﬁrst year and subsequent
Table 3 Comparison of some features between models in osteoporosis
Model Markov approach Time horizon
Restrictive assumptions about
transitions between states
Increased risk after
a prior fracture
Our model Microsimulation Lifetime No Yes
Zethraeus et al. [11] Cohort Lifetime Yes No
NICE [68] Microsimulation 10 years No Yes
Tosteson et al. [27] Cohort Lifetime No No
Schousboe et al. [65] Microsimulation Lifetime No Yes
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year effects of a fracture on future risks, costs, and quality of life
and it takes into account the characteristics of the selected popu-
lation and all the speciﬁcities of treatments such as compliance,
persistence, offset time of action, and adverse events.
There are potential limitations to our model. First, an
increased risk of subsequent fractures at sites different from that
of prior fractures is not modeled, with one exception. On the
other hand, the NICE model assumed that for simulated patients
suffering fractures at two different sites, only the greatest risk
adjustment was applied in calculating the risks of subsequent
fractures. The reason of our conservative assumption is that
fracture incidence (at a speciﬁc site) was estimated regardless of
the presence of fractures at other sites. Second, our analysis was
restricted to a direct health-care cost perspective, as recom-
mended for Belgian pharmacoeconomic evaluations [26]. We
have therefore not incorporated unrelated health-care costs in
life-years gained and indirect fracture costs related to productiv-
ity losses or to informal care provided by patient’s relatives.
Eventually, we have not incorporated long-term costs attribut-
able to clinical vertebral fracture.
Improving the quality of modeling is worthwhile but is not
sufﬁcient. The use of ever more sophisticated models to conduct
evaluations without improving the quality of the information
inputs will not increase the reliability of the results [8]. We
observed that fracture risk, fracture costs, and fracture disutility
have a signiﬁcant impact on the cost per QALY gained of treat-
ments. Such data are only available for a limited number of
countries. Further research is therefore needed to improve the
availability of data in the ﬁeld of osteoporosis, and in all coun-
tries. So, the widespread use of generic instruments in large
populations, and with long-term follow-up, has been recom-
mended to investigate the disutility of fractures [47,79]. Further-
more, few head-to-head comparisons of treatments have been
undertaken. Such comparisons would be very interesting.
Research is also needed to estimate long-term costs attributable
to hip and vertebral fracture and to establish long-term effective-
ness of treatments to assess the long-term cost-effectiveness of
anti-osteoporotic therapy.
Flexibility and adaptability of the model to different countries
were also primary considerations with the design of our model.
This model is ﬂexible and can analyze different patient groups
(such as patients having established osteoporosis or other clinical
risk factors), treatment alternatives, and cost perspectives, in any
country. It could also be adapted to test different assumptions
related to parameters or to model structure. Moreover, to make
accurate conclusions reﬂecting country speciﬁcities, the data
must be valid for the speciﬁc setting to which the model is applied
[11]. Therefore, country-speciﬁc data for all model inputs are
required. The developed model allows the speciﬁcation of
country-speciﬁc data (e.g., fracture and mortality rates, costs,
utilities, discontinuation rates). It would be great to have a large
database for different countries to assess potential differences in
cost per QALY gained of treatment between countries.
The developed model could be used to evaluate the cost-
effectiveness of the treatment and prevention of osteoporosis. To
assess the cost-effectiveness of new treatments, reliable data are
required on fracture reduction efﬁcacy (at speciﬁc sites), on treat-
ment cost, on the effect of treatment after stopping therapy, on
therapy adherence, and on adverse events. Non-adherence to
therapy results in a signiﬁcant change in cost-effectiveness.
Therefore, the effects of noncompliance and nonpersistence to
therapy should be investigated and should be an integral part of
economic evaluations in osteoporosis. Adverse events have also
been barely incorporated in cost-effectiveness analyses but there
may be of potential signiﬁcance. The model could also be used to
assess the cost-effectiveness of osteoporosis screening strategies
and to support recommendations about osteoporosis screening.
Because osteoporosis is a silent disease, screening for osteoporo-
sis has been recommended to identify and treat patients at high
risk of fracture, before any fracture occurs [80–82]. Few studies
have investigated the cost-effectiveness of screening for
osteoporosis. Such studies will be very useful for decision-makers
to guide rationale decisions. These analyses would require the
estimation of the screening cost per treated patient that could
then be used as a prior cost for the intervention strategy. This
model could also be used to estimate absolute lifetime risk of
fractures [28] and to assess the burden of osteoporosis in a
selected population.
Conclusion
High quality evaluations are required to provide the decision-
makers with accurate support for their decision-making
processes. This article illustrates the rationale for using micro-
simulation models to accurately assess the efﬁcacy of osteoporo-
sis management. This approach presents some major advantages
over cohort-based models, increasing the reliability of results and
being largely compatible with the existing state of the art,
evidence-based literature. The model described in this article
appears valid for use in economic evaluations in osteoporosis.
This model, like all models, should never be regarded as com-
pleted [13]. It would need to be updated as new evidence
becomes available to inform its structure or input values.
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